Stock Splits
By The Online Investor Staff, updated Fri., Mar. 5, 5:31 PM
| This Slide: #9 of 25 |
Slide #9. Moleculin Biotech, Inc. (NASDAQ:MBRX) — 1 for 6 Reverse Split
Announced:
1/29/2021
Stock Split:
1 for 6
Record Date:
1/29/2021
Pay Date:
2/1/2021
MBRX Optionable?:
No
Moleculin Biotech is a pharmaceutical company focused on the treatment of resistant cancers. Co.'s technologies are based on discoveries made at MD Anderson Cancer Center (MD Anderson). Co.'s primary product candidates is Annamycin, for which Food and Drug Administration allowed an Investigational New Drug Application to go into effect for a Phase 1/2 trial for the treatment of relapsed or refractory acute myeloid leukemia. Co. also has a license agreement with MD Anderson pursuant to which Co. had been granted a license for the patent and technology rights related to its WP1066 Portfolio and its close analogs, molecules targeting the modulation of primary oncogenic transcription factors. 
MBRX Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the MBRX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 87th percentile
(ranked higher than approx. 87% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
